# ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

> **NCT05290090** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Rituximab, Lenalidomide, Zanubrutinib and RCHOP

## Key facts

- **NCT ID:** NCT05290090
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05290090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05290090, "ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05290090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*